What this Trial Is About

Researchers are studying a new type of cancer treatment called CAR-T immunotherapy, which uses specially modified T cells to target and destroy cancer cells. This therapy is for patients with certain blood cancers that have not responded to other treatments, including forms of lymphoma, leukemia, and multiple myeloma. CAR-T therapy gives patients reprogrammed immune cells that can better recognize and attack cancer, overcoming some limitations of the body's natural immune responses. The study focuses on analyzing blood samples from patients undergoing CAR-T therapy at multiple time points before and after treatment, up to one year later. Researchers will examine epigenetic changes, microRNA levels, and different immune cell populations to understand how these factors relate to patient outcomes. The study will include about 35 patients per year over five years and will use samples collected during routine clinical care. Participants will provide peripheral blood samples at various stages, including before apheresis, on treatment day, and multiple days post-infusion. The research aims to link biological markers with clinical results to better understand and manage complications like inflammatory responses and neurological effects. This may help improve how CAR-T therapy is personalized and its safety monitored in patients with advanced blood cancers.

Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)